Literature DB >> 32875876

Assessing the Impact of Neurogenic Claudication on Outcomes Following Decompression With Lumbar Interbody Fusions in Patients With Lumbar Spinal Stenosis.

Michael L Martini1, Dominic A Nistal1, Brian C Deutsch1, Sean N Neifert1, Colin D Lamb1, John M Caridi1.   

Abstract

STUDY
DESIGN: Retrospective cohort study.
OBJECTIVES: To conduct the first comprehensive national-level study examining specific risks, outcomes, and costs surrounding surgical treatment of lumar spinal stenosis (LSS) in patients with and without neurogenic claudication (NC).
METHODS: Data for patients with or without NC who underwent decompression with a lumbar interbody fusion approached anteriorly (ALIF), posteriorly (PLIF), or laterally (LLIF) for LSS was collected from the 2013-2014 National Inpatient Sample using International Classification of Disease codes.
RESULTS: A total of 121 025 LSS cases without NC and 20 095 cases with NC were included in this study. The most significant complications associated with NC status by organ system included renal (P = .0030) and hematological complications (P = .0003). Multivariate regression controlling for key demographic and comorbidity variables showed that patients with NC did not have significantly higher odds of complication, non-home discharge, or extended hospitalization compared to patients without NC regardless of fusion type. Interestingly, NC patients had comparatively lower total charges for their hospitalization following PLIFs (P = .0001) and LLIFs (P < .0001), but not ALIFs (P = .6121).
CONCLUSION: NC does not appear to significantly increase odds of adverse outcomes following fusion in LSS. Given the large prevalence of LSS and coincidental NC, these findings may carry important implications in managing this challenging patient population and justifies future prospective investigation of this topic.

Entities:  

Keywords:  decompression; fusion; lumbar stenosis; national inpatient sample; neurogenic claudication; outcomes

Year:  2020        PMID: 32875876      PMCID: PMC7882831          DOI: 10.1177/2192568220902746

Source DB:  PubMed          Journal:  Global Spine J        ISSN: 2192-5682


Introduction

Lumbar spinal stenosis (LSS) is one of the leading pathologies related to lower back pain and disability in the population and the leading indication for patients older than 65 years to undergo spine surgery.[1-4] Patients can have numerous clinical presentations including localized back pain, radiculopathy, neurogenic claudication (NC), or even asymptomatic. NC, however, is one of the most common presentations.[5-7] The treatment of patients with LSS who present with NC is somewhat controversial. There is evidence in the literature for nonoperative management including calcitonin treatment, pain management, and patient surveillance. One systematic review assessed the effectiveness of nonoperative management in 21 clinical trials and concluded that little evidence exists to support nonoperative management of LSS with NC.[8] Previous studies have assessed surgical versus non-operative management for the treatment of LSS with NC.[9-13] Surgical decompression, which may be accompanied by fusion, for LSS has been found to improve symptoms immediately postoperatively, and more recently in the Spine Patient Outcomes Research Trial (SPORT), for up to 4 years postoperatively compared with conservative treatment.[14] Despite these previous findings, however, there is a deficit in the literature comparing patient outcomes following surgical management of LSS with and without co-presenting NC. It is evident in the literature that patients suffering from NC are a well-studied and interesting population, yet few studies assess the impact of NC secondary to LSS on clinical and economic outcomes. This study seeks to ameliorate this deficit by comprehensively characterizing the effect that NC has on clinical and resource utilization outcomes following decompression and various lumbar interbody fusion procedures for LSS using national-level data.

Materials and Methods

The National Inpatient Sample (NIS) of the Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality (AHRQ, Rockville, Maryland) was sampled to obtain data from 2013-2014. The NIS is structured as a stratified sample of 20% of nonfederal US hospitals with over 7 million hospitalizations annually, making it the largest all-payer national database.[15] An encoded weighting variable was applied to patient data to obtain regional and national estimates by accounting for the stratified clustering design of the database, as specified by HCUP (https://www.hcup-us.ahrq.gov/nisoverview.jsp). Our institutional review board has exempted studies involving the NIS from individual review. Patients were included if they had an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis code of spinal stenosis in the lumbar region without neurogenic claudication (ICD-9-CM code 724.02) or spinal stenosis in the lumbar region with neurogenic claudication (ICD-9-CM code 724.03). In some analyses, cohorts were further categorized according to the fusion type used alongside decompression to treat lumbar stenosis. To do this, we used procedure codes for primary or repeat lumbar interbody fusion anteriorly (ALIF; 81.06, 81.36), posteriorly (PLIF; 81.07, 81.37), or laterally (LLIF; 81.08, 81.38). We identified 121 025 lumbar stenosis cases without NC and 20 095 cases with NC that underwent an ALIF, PLIF, or LLIF procedure for surgical treatment. Demographic data was collected for both cohorts, including age, race, sex, primary insurance payer, income quartile by ZIP code, admission type, discharge disposition, hospital geographic region, comorbidities, and All Patients Refined Diagnosis Related Groups (APRDRG) scores for mortality risk and severity of illness. Procedure type was also considered as a covariate when assessing overall complication rates across groups. The primary outcomes examined included in-hospital mortality rate, overall complication rate, complication rate by organ system, and other more specific perioperative complications faced by spine surgery patients. Secondary outcome and resource utilization metrics included length of hospital stay, discharge disposition, and total charges for the hospital visit. For purposes of data analysis, any discharge that was not to home was considered a nonhome discharge. In addition, an extended hospitalization was defined as a length of hospital stay that was greater than the 75th percentile of hospitalization lengths for the entire study population. Organ system complications were determined for neurological (seizures 345.xx, stroke 433.x or 434.x, transient cerebral ischemia 435.x, and neurological complications after procedure 997.01 or 997.09), pulmonary (514, 518.xx, or 512.xx), cardiac (410.xx or 785.xx), peripheral vascular (venous thromboembolic 453.xx or 415.xx), renal (584.x), gastrointestinal (578.x, 560.1, or 00845), infectious (041.xx, 38.xx, 320.xx, 324.1, 481-486, 507.0, 595.0, 790.7, 995.9x, 996.64, 997.31, 998.59, 999.31), and hematological (285.xx or 998.1x, or red blood cell transfusion 99.04) systems. Sodium disturbance complications (253.5, 253.6, 276.0, or 276.1) were also tracked, along with cases required a tracheostomy (31.1, 31.2, 31.21, or 31.29) or gastrojejunostomy (43.1, 43.11, 43.19, or 46.32). Statistical analysis was implemented with SAS 9.4 (SAS Institute, Cary, NC, 2013). Categorical variables were assessed using chi-square tests, while Fisher’s exact test evaluated contingency tables with expected counts less than one under the null hypothesis of independence. The means of continuous variables between the two cohorts were compared using two-sided, two-sample T tests. Univariate regression models were constructed to assess primary and secondary outcomes following surgery for LSS based on whether the patients also had NC. Multivariable regression models were constructed to assess primary and secondary outcomes, including odds of complication, nonhome discharge, extended hospitalization, and total charges, while controlling for important differences in demographic and comorbidity characteristics between the cohorts. To do this, models incorporated predictor variables previously identified as differing significantly between the groups or were established factors known to impact surgical outcomes. Notably, these included age, along with sex, race, hospital geographic region, primary insurance payer, income quartile by ZIP code, chronic blood loss anemia, depression, diabetes mellitus with complications, hypertension, obesity, perivascular disease, and renal failure. These models were further stratified by the fusion type (ALIF, PLIF, and LLIF) performed along with decompression to account for procedure-level differences in outcomes. P < .05 was used to determine statistical significance. The variance inflation factor (VIF) was examined to assess model multicollinearity. Figures were produced using Prism 7 (Graphpad, La Jolla, CA, 2017).

Results

Demographics

We identified a weighted total of 121 025 LSS cases without NC and 20 095 cases with NC that underwent an ALIF, PLIF, or LLIF procedure along with decompression for treatment. Table 1 summarizes baseline demographic characteristics of LSS cases grouped by presence of NC. Comparison of demographic characteristics revealed differences in the distributions of age (P < .0001), sex (P = .0091), primary insurance payer (P < .0001), and discharge disposition (P < .0001) in the 2 cohorts (Table 1). LSS patients with NC were more likely to be older, male, insured by Medicare, and experience nonroutine discharge.
Table 1.

Demographics of the Study Population by Neurogenic Claudication Status.

Neurogenic Claudication Status
LSSLSS + NC P
Age, y
 0-4410 035 (8.5)660 (3.4)<.0001
 45-6452 040 (44.1)7365 (37.8)
 65-7439 525 (33.5)7720 (39.6)
 75+16 360 (13.9)3740 (19.2)
Sex
 Male50 750 (41.9)8875 (44.2).0091
 Female70 275 (58.1)11 220 (55.8)
Race
 White96 605 (84.7)15 845 (85.6).2917
 Black8305 (7.3)1320 (7.2)
 Hispanic4965 (4.3)745 (4.0)
 Asian1015 (0.9)205 (1.1)
 Other3210 (2.8)395 (2.1)
Insurance
 Medicare62 305 (51.5)12 305 (61.3)<.0001
 Medicaid5100 (4.2)635 (3.2)
 Private45 435 (37.6)6225 (31.0)
 Other8080 (6.7)895 (4.5)
Median income by zip code
 0th-25th percentile27 255 (22.9)4560 (23.2).4941
 26th-50th percentile33 550 (28.2)5830 (29.7)
 51th-75th percentile31 220 (26.3)5040 (25.7)
 76th-100th percentile26 880 (22.6)4215 (21.4)
Discharge disposition
 Home (routine)94 995 (78.5)14 845 (73.9)<.0001
 Short-term care505 (0.4)150 (0.7)
 Skilled nursing facility0 (0)0 (0)
 Died in hospital105 (0.1)20 (0.1)
 Designated cancer center or other25 400 (21.0)5080 (25.3)
Hospital division
 New England5145 (4.2)975 (4.8).3872
 Middle Atlantic16 230 (13.4)2135 (10.6)
 East North Central22 170 (18.3)4070 (20.2)
 West North Central9640 (8.0)1665 (8.3)
 South Atlantic27 145 (22.4)4625 (23.0)
 East South Central10 875 (9.0)1540 (7.7)
 West South Central12 790 (10.6)1900 (9.5)
 Mountain9650 (8.0)1840 (9.2)
 Pacific7390 (6.1)1345 (6.7)
Admission type
 Elective112 385 (93.1)18 970 (94.6).0789
 Nonelective (urgent or emergency)8335 (6.9)1090 (5.4)
APRDRG Mortality Score
 Minor likelihood of dying98 775 (81.6)15 650 (77.9)<.0001
 Moderate likelihood of dying17 070 (14.1)3390 (16.9)
 Major likelihood of dying4255 (3.5)880 (4.3)
 Extreme likelihood of dying930 (0.8)175 (0.9)
APRDRG Severity Score
 Minor loss of function60 505 (50.0)9270 (46.1)<.0001
 Moderate loss of function49 800 (41.1)8770 (43.6)
 Major loss of function9795 (8.1)1950 (9.7)
 Extreme loss of function930 (0.8)105 (0.6)

Abbreviations: LSS, lumbar spinal stenosis; NC, neurogenic claudication; APRDRG, All Patients Refined Diagnosis Related Group.

Demographics of the Study Population by Neurogenic Claudication Status. Abbreviations: LSS, lumbar spinal stenosis; NC, neurogenic claudication; APRDRG, All Patients Refined Diagnosis Related Group. A higher proportion of LSS patients with NC also tended to have certain comorbid conditions compared to LSS patients without NC, including anemia from chronic blood loss (P = .0136), depression (P = .0174), diabetes mellitus with complications (P = .0011), hypertension (P < .0001), obesity (P = .0237), peripheral vascular disease (P = .0042), and renal failure (P = .0002) (Figure 1).
Figure 1.

Comorbidity landscape of LSS patients with and without NC undergoing decompression and lumbar interbody fusion procedures. P < .05 was set as the threshold for statistical significance. *Indicates P < .05. **Indicates P < .01. ***Indicates P < .0001. LSS, lumbar spinal stenosis; NC, neurogenic claudication.

Comorbidity landscape of LSS patients with and without NC undergoing decompression and lumbar interbody fusion procedures. P < .05 was set as the threshold for statistical significance. *Indicates P < .05. **Indicates P < .01. ***Indicates P < .0001. LSS, lumbar spinal stenosis; NC, neurogenic claudication. Further examination of baseline characteristics in the LSS patient cohorts revealed that patients with NC also had higher mean APRDRG Risk Mortality (P < .0001) and Disease Severity scores (P = .0003), as well as a greater number of diagnoses (P < .0001) and chronic conditions (P < .0001) on record (Table 2).
Table 2.

Differences in the Baseline Characteristics of the Study Population by Neurogenic Claudication Status.

Neurogenic Claudication Status
LSSLSS + NC P
APRDRG Risk Mortality
 Mean (95% CI)1.234 (1.226-1.242)1.282 (1.263-1.302)<.0001
 SEM0.0040.010
APRDRG Severity
 Mean (95% CI)1.596 (1.584-1.609)1.646 (1.620-1.672).0003
 SEM0.0070.013
Age, y
 Mean (95% CI)62.59 (62.381-62.799)65.893 (65.478-66.308)<.0001
 SEM0.1070.212
Number of diagnoses on record
 Mean (95% CI)9.374 (9.255-9.492)9.991 (9.759-10.223)<.0001
 SEM0.0610.118
Number of chronic conditions on record
 Mean (95% CI)4.639 (4.577-4.701)5.592 (5.475-5.709)<.0001
 SEM0.0310.060
Number of procedures on record
 Mean (95% CI)5.346 (5.290-5.402)5.438 (5.311-5.566).1343
 SEM0.0280.065

Abbreviations: LSS, lumbar spinal stenosis; NC, neurogenic claudication; APRDRG, All Patients Refined Diagnosis Related Group; CI, confidence interval; SEM, standard error of the mean.

Differences in the Baseline Characteristics of the Study Population by Neurogenic Claudication Status. Abbreviations: LSS, lumbar spinal stenosis; NC, neurogenic claudication; APRDRG, All Patients Refined Diagnosis Related Group; CI, confidence interval; SEM, standard error of the mean.

Outcomes

Univariate regression models were built to examine how in-hospital mortality and complication rates varied according to NC status and procedure type (Table 3). In-hospital mortality rates did not differ between NC and non-NC patients, despite the NC group’s elevated APRDRG Risk Mortality scores. The NC group did, however, have a higher overall rate of complication (37.02%) compared with the non-NC group (33.94%) across all procedures (odds ratio [OR] 1.144; 95% CI 1.049-1.248; P < .0023). Repeating this analysis on specific procedural subsets revealed procedure-level differences in complication rates across LSS patients depending on NC status. For example, LSS patients with NC experienced higher odds of complication following an LLIF procedure (OR 1.145; 95% CI 1.031-1.273; P = .0118) but not ALIF (P = .2489) or PLIF (P = .0863) procedures.
Table 3.

Univariate Regression Models Evaluating the Impact of Neurogenic Claudiation Status on In-hospital Mortality and Complications by Procedure Type.

Neurogenic Claudication Status
LSSLSS + NCOR (95% CI) P
In-hospital mortality rate
 Weighted count105201.147 (0.395-3.331).8007
 % of patients affected0.090.10
All complications
 Weighted count41 07574401.144 (1.049-1.248).0023
 % of patients affected33.9437.02
ALIF complicationsLSS (n = 14 800)LSS + NC (n = 1965)
 Weighted count52857651.148 (0.908-1.451).2489
 % of patients affected35.7138.93
PLIF complicationsLSS (n = 36 870)LSS + NC (n = 5625)
 Weighted count11 70019401.133 (0.982-1.306).0863
 % of patients affected31.7334.49
LLIF complicationsLSS (n = 69 355)LSS + NC (n = 12 505)
 Weighted count24 09047351.145 (1.031-1.273).0118
 % of patients affected34.7337.86

Abbreviations: OR, odds ratio; CI, confidence interval; LSS, lumbar spinal stenosis; NC, neurogenic claudication; ALIF, anterior lumbar interbody fusion; PLIF, posterior lumbar interbody fusion; LLIF, lateral lumbar interbody fusion.

Univariate Regression Models Evaluating the Impact of Neurogenic Claudiation Status on In-hospital Mortality and Complications by Procedure Type. Abbreviations: OR, odds ratio; CI, confidence interval; LSS, lumbar spinal stenosis; NC, neurogenic claudication; ALIF, anterior lumbar interbody fusion; PLIF, posterior lumbar interbody fusion; LLIF, lateral lumbar interbody fusion. Univariate regression analyses also examined the impact of NC status on certain complication risks by organ system using a selected set of common surgical complications categorized by organ system (Figure 2). This analysis revealed LSS patients with NC carried significantly higher odds of complication in certain organ systems, including renal (OR 1.347, 95% CI 1.106-1.640; P = .0030) and hematological complications (OR 1.193; 95% CI 1.085-1.313; P = .0003). Interestingly, patients with NC did not have significantly higher odds of neurological complications (P = .3664).
Figure 2.

Odds ratios of complications by organ system following decompression and surgical fusion for LSS in patients with NC compared to those without NC. Odds ratios obtained through univariate logistic regressions. *Indicates P < .05. **Indicates P < .01. ***Indicates P < .0001. LSS, lumbar spinal stenosis; NC, neurogenic claudication.

Odds ratios of complications by organ system following decompression and surgical fusion for LSS in patients with NC compared to those without NC. Odds ratios obtained through univariate logistic regressions. *Indicates P < .05. **Indicates P < .01. ***Indicates P < .0001. LSS, lumbar spinal stenosis; NC, neurogenic claudication. A more detailed assessment of the complication profiles of these cohorts was obtained by building univariate regression models for specific perioperative complications that may result following surgery on the spine (Table 4). Among the 20 specific complications examined, patients with NC only had significantly higher odds of experiencing renal failure (OR 1.353; 95% CI 1.112-1.647; P = .0025) and postoperative anemia (OR 1.245; 95% CI 1.106-1.403; P = .0003) compared with patients without NC.
Table 4.

Univariate Regression Models Evaluating the Impact of Neurogenic Claudication Status on Certain Surgical Complications Across Organ Systems.

Neurogenic Claudication Status
LSSLSS + NCa OR (95% CI) P
Myocardial infarction
 Weighted count280601.292 (0.691-2.417).4227
 % of patients affected0.230.30
Cardiac arrest
 Weighted count6351050.996 (0.618-1.605).9866
 % of patients affected0.520.52
Renal failure
 Weighted count27156051.353 (1.112-1.647).0025
 % of patients affected2.243.01
Pneumonia
 Weighted count9851851.132 (0.780-1.645).5138
 % of patients affected0.810.92
Deep venous thrombosis
 Weighted count120*0.251 (0.034-1.856).1756
 % of patients affected0.10*
Venous thromboembolism
 Weighted count7101551.318 (0.899-1.931).1567
 % of patients affected0.590.77
Acute respiratory failure
 Weighted count630850.812 (0.482-1.367).4332
 % of patients affected0.520.42
Pulmonary embolism
 Weighted count285751.587 (0.908-2.775).1050
 % of patients affected0.240.37
Postoperative anemia
 Weighted count18 49036851.245 (1.106-1.403).0003
 % of patients affected15.2818.34
Oliguria/Anuria
 Weighted count150451.809 (0.869-3.764).1130
 % of patients affected0.120.22
Urinary complication
 Weighted count11101700.922 (0.645-1.318).6554
 % of patients affected0.920.85
Wound dehiscence
 Weighted count70*0.860 (0.268-2.765).8007
 % of patients affected0.06*
Wound infection
 Weighted count180250.836 (0.328-2.135).7087
 % of patients affected0.150.12
Systemic inflammatory response syndrome
 Weighted count235401.025 (0.485-2.169).9475
 % of patients affected0.190.20
Severe sepsis
 Weighted count150251.004 (0.389-2.590).9937
 % of patients affected0.120.12
Septic shock
 Weighted count85151.063 (0.312-3.625).9223
 % of patients affected0.070.07
Urinary tract infection
 Weighted count30655151.012 (0.821-1.249).9082
 % of patients affected2.532.56
Sodium disturbance complication
 Weighted count43658301.152 (0.948-1.399).1557
 % of patients affected3.614.13
Tracheostomy
 Weighted count400NANA
 % of patients affected0.030.00
Gastrojejunostomy
 Weighted count35*0.860 (0.106-6.988).8881
 % of patients affected0.03*

Abbreviations: OR, odds ratio; CI, confidence interval; LSS, lumbar spinal stenosis; NC, neurogenic claudication; NA, not applicable.

aAsterisk indicates that the actual value was not reported to protect patient privacy, as specified by HCUP.

Univariate Regression Models Evaluating the Impact of Neurogenic Claudication Status on Certain Surgical Complications Across Organ Systems. Abbreviations: OR, odds ratio; CI, confidence interval; LSS, lumbar spinal stenosis; NC, neurogenic claudication; NA, not applicable. aAsterisk indicates that the actual value was not reported to protect patient privacy, as specified by HCUP. Secondary outcomes and resource utilization metrics were also examined through univariate regression analysis to provide a more complete picture of how the outcomes between patients with and without NC group might differ following various lumbar interbody fusion procedures for LSS (Table 5). Patients with NC faced significantly higher odds of a nonhome discharge (OR 1.290; 95% CI 1.181-1.409; P < .0001). In addition, patients with NC did have higher odds of an extended hospitalization (OR 1.124; 95% CI 1.017-1.241; P = .0219), defined as a hospital stay greater than the 75th percentile of hospitalization lengths for the entire study population. Despite these findings, a total charges analysis revealed that there was not a significant difference between the average total charges for a hospital visit between patients with NC (mean $104 997; 95% CI $100 675-$109 318) and without NC (mean $109 226; 95% CI $106 507-$111 946) at the univariate level (P = .0512).
Table 5.

Univariate Regression Models Evaluating the Impact of Neurogenic Claudication Status on Resource Utilization and Secondary Clinical Outcomes.

Neurogenic Claudication Status
LSSLSS + NC P
Mean length of stay (days)
 Mean (95% CI)3.631 (3.575-3.686)3.698 (3.590-3.806).2233
 SEM0.0280.055
Extended hospitalization
 Weighted count25 5504645.0219
 % of patients affected21.1123.12
 OR (95% CI)1.124 (1.017-1.241)
Nonhome discharge
 Weighted count26 0405250<.0001
 % of patients affected21.5126.13
 OR (95% CI)1.290 (1.181-1.409)
Total charges ($)
 Mean (95% CI)109 226 (106 507-111 946)104 997 (100 675-109 318).0512
 SEM13872204

Abbreviations: LSS, lumbar spinal stenosis; NC, neurogenic claudication; CI, confidence interval; OR, odds ratio; SEM, standard error of the mean.

Univariate Regression Models Evaluating the Impact of Neurogenic Claudication Status on Resource Utilization and Secondary Clinical Outcomes. Abbreviations: LSS, lumbar spinal stenosis; NC, neurogenic claudication; CI, confidence interval; OR, odds ratio; SEM, standard error of the mean. A series of multivariate regression models were constructed for each procedural technique to better evaluate how NC status impacted primary and secondary outcomes after controlling for key demographic and comorbidity variables. Interestingly, this analysis revealed that NC status did not significantly affect the odds of complication, nonhome discharge, or extended hospitalization across any of the procedure types after controlling for age, sex, race, primary payer status, hospital geographic division, and income quartile, as well as comorbidities, including chronic blood loss anemia, depression, diabetes mellitus with complications, hypertension, lymphoma, obesity, perivascular disease, and renal failure (Table 6). In addition, we noted a small but significant difference in total charges depending on the procedure type. Patients with NC actually experienced lower total charges than patients without NC following PLIFs (estimate = −$4893; standard error [SE] = $1275; P = .0001) and LLIFs (estimate = −$3,489; SE = $478; P < .0001), but not ALIFs (estimate = −$575; SE = $1034; P = .6121).
Table 6.

Multivariate Regression Models Evaluating the Impact of Neurogenic Claudication Status on Relevant Primary and Secondary Outcome Measures.a

OutcomeOR (95% CI)/Estimate (SE) P
Anterior lumbar interbody fusion
 Complication0.952 (0.752-1.206).6847
 Nonhome discharge0.939 (0.687-1.282).6910
 Extended hospitalization1.009 (0.756-1.347).9510
 Total charges, $−525 (1034).6121
Posterior lumbar interbody fusion
 Complication1.065 (0.903-1.255).4563
 Nonhome discharge1.023 (0.846-1.235).8168
 Extended hospitalization0.968 (0.802-1.168).7329
 Total charges, $−4893 (1275).0001
Lateral lumbar interbody fusion
 Complication1.058 (0.943-1.187).3401
 Nonhome discharge1.020 (0.898-1.158).7607
 Extended hospitalization1.121 (0.985-1.276).0834
 Total charges, $−3489 (478)<.0001

Abbreviations: OR, odds ratio; CI, confidence interval; SE, standard error.

aModels control for demographic variables, such as age, sex, race, primary payer status, hospital census division, and income quartile, as well as comorbidities, including chronic blood loss anemia, depression, diabetes mellitus with complications, hypertension, lymphoma, obesity, perivascular disease, and renal failure.

Multivariate Regression Models Evaluating the Impact of Neurogenic Claudication Status on Relevant Primary and Secondary Outcome Measures.a Abbreviations: OR, odds ratio; CI, confidence interval; SE, standard error. aModels control for demographic variables, such as age, sex, race, primary payer status, hospital census division, and income quartile, as well as comorbidities, including chronic blood loss anemia, depression, diabetes mellitus with complications, hypertension, lymphoma, obesity, perivascular disease, and renal failure.

Discussion

Demographics and Comorbidities

Comparison of the demographic and comorbidity landscapes of LSS patients with and without NC revealed several important differences that would be of interest to neurosurgeons, neurologists, and other clinicians that often interact with these groups of patients. First, these groups showed statistically significant differences in the distributions of their ages, sex, primary insurance payer, and discharge disposition. In particular, LSS patients who also had NC tended to be older, male, insured by Medicare rather than a private payer, and nonroutinely discharged. Some of these population-level differences may suggest a less favorable clinical picture that is often associated with worse outcomes in previous studies of spine surgeries. In particular, previous studies have shown that older patients were more likely to experience more complications, in-hospital mortalities, and longer hospitalizations compared with the general adult population following various fusion and decompression surgeries.[16] A separate study focusing on elective lumbar spinal surgeries found that patients with private insurance have slightly greater improvement in their postoperative quality of life compared to patients with public insurance, though both groups experienced significant functional improvement overall postoperatively.[17] Similarly, we noted a significant difference in the prevalence of certain surgically relevant comorbidities between patients with and without NC. In particular, patients with NC were more likely to also have chronic blood loss anemia, depression, diabetes mellitus with complications, hypertension, obesity, peripheral vascular disease, and renal failure. Nearly all these comorbidities have been linked to worse clinical outcomes following spinal surgeries.[18-22] Taken together, our analysis of the national populations of LSS patients suggest that those with NC carry important differences in their demographic and comorbidity profiles that could significantly affect their perioperative clinical outcomes and resource utilization following spinal surgery. While these findings alone present important considerations for surgeons and clinicians caring for these patients in the perioperative period, these variables must be carefully controlled for in statistical analysis between these 2 cohorts. Therefore, we constructed multivariate logistic regression models that account for these differences to better characterize how NC impacts clinical outcomes across various interbody fusion approaches for treating LSS.

Primary Outcomes: Complications and Mortality

Patients with symptomatic NC secondary to LSS represent an interesting cohort that has been studied within several medical and surgical contexts. However, no study to date has elucidated how the outcomes of this population compare to those of non-NC LSS patients following decompression and lumbar fusion procedures who likely presented with other symptomatology. Our study findings indicate that both groups showed low in-hospital mortality (<0.1% in each cohort), while the total complication rate across all 3 procedures was higher in patients with NC (P < .0023). However, when evaluating complication rate by independent procedure type, only LLIF remained significantly different. This observation could be due to the extent of stenosis where LLIF may be less suitable for severe stenosis, leading to more challenging procedures and greater rates of complications.[23] Extensive psoas muscle dissection and lumbar plexus neuropathies may also contribute to a higher complication rate. Overall, systemic complication rates between these groups were relatively low and did not differ significantly. The fact that the presence of symptomatic NC does not affect outcomes may be due to the varying range of clinical presentation for similarly presenting radiographic disease. Correlation between radiographic findings, extent of disease, and clinical symptoms are often nonspecific and inconsistently demonstrated in the literature.[24,25] For example, one study prospectively assessed the relationship of symptomatic gait impairment in patients with LSS and found no correlation between severity of symptoms and extent of disease on magnetic resonance imaging.[26] As such, patients with more severe stenosis and worse clinical outcomes may be likely found in both the NC and non-NC cohorts, potentially offering a partial explanation as to why we observed similar clinical outcome profiles between the cohorts in this study. Our analyses of clinical outcomes are also informative of the complexity of this patient population. Intuitively, a worse clinical presentation would lead to a more complicated and morbid postoperative course, however in this population, that is not the case. It is likely that the clinical presentation of NC in the population is inconsistent with the extent of LSS as well as other degenerative deformities, such as bony lateral recess stenosis and spondylolisthesis.

Secondary Outcomes: Resource Utilization

Comparison of the 2 LSS cohorts in this study through carefully controlled multivariate regression modeling found that the only significant difference in resource utilization was total charges. Interestingly, patients with NC had significantly lower total charges for their hospital visits than non-NC patients following PLIF and LLIF fusion approaches. One of the potential drivers of this effect might be related to NC patients experiencing more profound symptom relief after their operation, which in turn, could lead to decreased time to ambulation, decreased physical therapy utilization, and fewer assistive devices. These lower total charges may also, in part, be due to the potentially increased utilization of nonoperative therapies by symptomatic NC patients prior to their hospitalization for surgery. Patients who are symptomatic with NC secondary to LSS most likely seek nonoperative therapies prior to undergoing lumbar decompression and fusion. As such, the utilization of nonoperative management preoperatively may influence resource utilization and cost measures during the intrahospital and postoperative periods. Though no studies have examined the direct effect that nonoperative care prior to hospitalization may have on intra- and postoperative costs and resource utilization, a retrospective study did review the costs for NC patients receiving nonoperative care prior to lumbar decompression and fusion and found a large preoperative cost burden with minimal clinical benefit.[27] Many of the patients in that study were using services such as chiropractors, physical therapists, and pain specialist prior to their procedure. Having these resources in place preoperatively may favorably influence patient length of stay and disposition from the hospital, thus reducing cost and improving resource utilization at the time of fusion. It is important to note that while the results from this study and others provide some initial thoughts regarding the cost burden and efficiency of healthcare utilization in the perioperative period for these patient populations, further investigation is warranted to advance discussions of this topic in realms of policy, health care delivery, and research as LSS and NC are likely to become increasingly important issues in surgical spine practices.

Limitations

A primary limitation of this study was its retrospective design. Retrospective studies are unable to discern temporal relationships and may include selection bias in the data. A second limitation pertains to the inherent design of the NIS. The NIS does not track events that occur outside the hospital. Therefore, mortality and complications with delayed onsets may not be completely represented. A third limitation is that NIS data is accessed through ICD-9 codes, meaning that certain data not ICD-9-encoded could not be considered. These might include extent of spinal stenosis, severity of NC, anesthesia metrics, number of levels involved, intraoperative blood loss, surgery duration, or postoperative mobilization time. Finally, it is important to acknowledge that a certain degree of heterogeneity may underlie national-level data, as surgical cases occur under a variety of circumstances with surgeon- and team-level differences inherent to the practice. On the other hand, this intrinsic diversity may also enhance the generalizability of these findings.

Conclusions

NC is one of the most common symptomatic presentations for patients with LSS. Despite the high prevalence of LSS presenting with NC, no studies have investigated how LSS patients with NC fare in lumbar spinal surgery compared with LSS patients who do not have co-presenting NC. This is one of the first studies comprehensively characterize the effect that NC has on the clinical and economic outcomes following decompression with various lumbar interbody fusion procedures for LSS. Our results indicate that there are not obvious distinctions between outcomes in the 2 cohorts and support the need for prospective clinical studies to further assess outcomes by NC, as this knowledge could influence management of this challenging patient population.
  27 in total

1.  Surgical versus nonoperative treatment for lumbar spinal stenosis four-year results of the Spine Patient Outcomes Research Trial.

Authors:  James N Weinstein; Tor D Tosteson; Jon D Lurie; Anna Tosteson; Emily Blood; Harry Herkowitz; Frank Cammisa; Todd Albert; Scott D Boden; Alan Hilibrand; Harley Goldberg; Sigurd Berven; Howard An
Journal:  Spine (Phila Pa 1976)       Date:  2010-06-15       Impact factor: 3.468

Review 2.  Surgical research using national databases.

Authors:  Ram K Alluri; Hyuma Leland; Nathanael Heckmann
Journal:  Ann Transl Med       Date:  2016-10

Review 3.  What interventions improve walking ability in neurogenic claudication with lumbar spinal stenosis? A systematic review.

Authors:  Carlo Ammendolia; Kent Stuber; Christy Tomkins-Lane; Michael Schneider; Y Raja Rampersaud; Andrea D Furlan; Carol A Kennedy
Journal:  Eur Spine J       Date:  2014-03-15       Impact factor: 3.134

4.  Long-Term Costs of Maximum Nonoperative Treatments in Patients With Symptomatic Lumbar Stenosis or Spondylolisthesis that Ultimately Required Surgery: A 5-Year Cost Analysis.

Authors:  Owoicho Adogwa; Mark A Davison; Victoria D Vuong; Syed Khalid; Daniel T Lilly; Shyam A Desai; Jessica Moreno; Joseph Cheng; Carlos Bagley
Journal:  Spine (Phila Pa 1976)       Date:  2019-03-15       Impact factor: 3.468

5.  Clinical results and limitations of indirect decompression in spinal stenosis with laterally implanted interbody cages: results from a prospective cohort study.

Authors:  Gregory M Malham; Rhiannon M Parker; Ben Goss; Carl M Blecher
Journal:  Eur Spine J       Date:  2015-02-14       Impact factor: 3.134

6.  A multicenter, prospective, randomized trial evaluating the X STOP interspinous process decompression system for the treatment of neurogenic intermittent claudication: two-year follow-up results.

Authors:  James F Zucherman; Ken Y Hsu; Charles A Hartjen; Thomas F Mehalic; Dante A Implicito; Michael J Martin; Donald R Johnson; Grant A Skidmore; Paul P Vessa; James W Dwyer; Stephen T Puccio; Joseph C Cauthen; Richard M Ozuna
Journal:  Spine (Phila Pa 1976)       Date:  2005-06-15       Impact factor: 3.468

7.  Lumbar spinal stenosis. Clinical and radiologic features.

Authors:  T Amundsen; H Weber; F Lilleås; H J Nordal; M Abdelnoor; B Magnaes
Journal:  Spine (Phila Pa 1976)       Date:  1995-05-15       Impact factor: 3.468

Review 8.  Nonoperative treatment of lumbar spinal stenosis with neurogenic claudication: a systematic review.

Authors:  Carlo Ammendolia; Kent Stuber; Linda K de Bruin; Andrea D Furlan; Carol A Kennedy; Yoga Raja Rampersaud; Ivan A Steenstra; Victoria Pennick
Journal:  Spine (Phila Pa 1976)       Date:  2012-05-01       Impact factor: 3.468

9.  Association between preoperative activity level and functional outcome at 12 months following surgical decompression for lumbar spinal stenosis.

Authors:  Galal Elsayed; Matthew S Erwood; Matthew C Davis; Esther C Dupépé; Samuel G McClugage; Paul Szerlip; Beverly C Walters; Mark N Hadley
Journal:  J Neurosurg Spine       Date:  2018-07-06

10.  Two-year results of interspinous spacer (X-Stop) implantation in 175 patients with neurologic intermittent claudication due to lumbar spinal stenosis.

Authors:  Johannes Kuchta; Rolf Sobottke; Peer Eysel; Patrick Simons
Journal:  Eur Spine J       Date:  2009-04-22       Impact factor: 3.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.